Exploring how gut microbes affect kidney disease
The Influence of Chronic Kidney Disease on Intestinal Transport of Gut Microbial Metabolites
This study is trying to see how gut bacteria affect kidney disease by looking at certain substances in the intestines of people with kidney problems compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven, Vlaams Brabant) |
| Trial ID | NCT01752738 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of the colonic microbiome in chronic kidney disease by examining the intestinal transport of specific microbial metabolites, such as indoxyl sulfate and p-cresyl sulfate. Researchers will collect colonic biopsies from patients with chronic kidney disease and compare the findings to healthy controls to understand the mechanisms of metabolite uptake and metabolism. The goal is to uncover insights that could lead to new therapeutic targets for treating chronic kidney disease.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 85 with chronic kidney disease up to stage III who are scheduled for a colonoscopy.
Not a fit: Patients with a history of gastrointestinal diseases, colon surgery, or those who have received organ transplants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could identify new treatment strategies for chronic kidney disease by targeting microbial metabolites.
How similar studies have performed: While the specific mechanisms of intestinal transport for these metabolites are not well-studied, related research on the gut microbiome's impact on kidney disease is emerging, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 and ≤ 85 years * Chronic kidney disease ≤ stage III (KDOQI), i.e., estimated glomerular filtration rate (MDRD) \< 60 ml/min/m² or need of dialysis therapy 27 * Scheduled colonoscopy for diagnostic purposes * Written informed consent Exclusion Criteria: * History of gastro-intestinal disease (e.g., inflammatory bowel disease) * History of colon surgery * Recipient of a renal or other solid organ transplant * Exposure to antibiotics or drug therapy with a known influence on intestinal transporters (e.g., P-gp) or enzymes during 2 weeks before colonoscopy
Where this trial is running
Leuven, Vlaams Brabant
- University Hospitals Leuven — Leuven, Vlaams Brabant, Belgium (Recruiting)
Study contacts
- Principal investigator: Bjorn Meijers, MD, PhD — UZ Leuven
- Study coordinator: Sander Derjongh
- Email: sander.dejongh@kuleuven.be
- Phone: + 32 16 342352
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.